compiledVersion 1generation-2 · epoch 1

In adults with type 2 diabetes and coronary artery disease, does metformin reduce major cardiovascular events compared with glipizide?

Question scope

Current conclusion

50%

belief

unreplicated

supports · causal

Metformin reduces risk of Major adverse cardiovascular events: belief 0.50 [0.25, 0.70], unreplicated (single unreplicated family)

Based on 2 included evidence families in epoch 1.

Source-linked items used by the compiled claim. Evidence families prevent repeated reports from being counted as independent studies.

paperqualifies

Evidence family A

papersupports

Evidence family B

missing replicationPriority 0.50

Exactly one independent evidence family supports this claim. Leave it out and no direct evidence remains.

Proposed experiment

0.28

information gain, where 1 settles the question

18%

expected narrowing of the belief band

Randomized trial of Metformin against glipizide, in adults with type 2 diabetes and coronary artery disease.
Primary outcome: Major adverse cardiovascular events.
Must not share investigators, sites, or data with existing evidence families.
Belief would move to 96% if the result confirms the claim, or to 40% if it contradicts it.

Version 1 · epoch 1Seeded from the corpus: two source records, one causal claim, belief with lineage.